Regorafenib is a multiple protein kinases inhibitor that is very similar to sorafenib, and it enhances SHP-1 activity in HCC and CRC to promote apoptosis by inhibiting STAT3 signaling [98,99]. This evidence concerns the gene NR0B2 and hepatocellular carcinoma.